Key points from article :
Dr. Alex Colville and Laura Deming launch age1, a venture capital firm with $35 million to back longevity biotech companies.
Dr. Colville, an expert in aging biology, leads age1 as the General Partner, making it a unique longevity biotech fund.
The firm's mission is to shift focus from sick care to health preservation and extension by targeting aging and age-related diseases.
Notably, age1's launch aligns with a pivotal moment in the longevity biotech industry, echoing Loyal's FDA approval for a study on healthspan and lifespan in dogs.
age1 plans to support early-stage founders and companies, offering strategic guidance and access to a talent network.
Laura Deming believes age1 is a pivotal player in the longevity biotech industry, working towards the goal of extending healthy lifespans.
